Table 5 Comparison of diagnostic performance of PSA, PSA at 4 ng/mL cutoff, age, and the 25-Gene Panel urine test and their combinations for PCa diagnosis in the PSA Cohort

From: Development and validation of a 25-Gene Panel urine test for prostate cancer diagnosis and potential treatment follow-up

  Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI) OR (95% CI) AUC (95% CI)
PSA 36.3% (43.1–29.5%) 92.3% (94.8–88.8%) 80.5% (88.8–72.1%) 62.5% (67.7–57.3%) 6.7 (12.2–3.9) 0.710 (0.759–0.661)
PSA-4 83.9% (89.1–78.8%) 30.2% (36.2–24.1%) 51.1% (56.6–45.6%) 68.4% (77.6–59.2%) 2.3 (3.7–1.4) 0.588 (0.642–0.534)
Age 1.0% (2.5–0.4%) 97.8% (99.7–95.8%) 28.6% (62.0–4.9%) 53.3% (58.2–48.5%) 0.5 (2.4–0.1) 0.516 (0.572–0.460)
25-Gene 88.6% (93.1–84.1%) 93.2% (96.6–90.0%) 91.9% (95.9–88.0%) 90.4% (94.2–86.6%) 107.3 (213.2–54.0) 0.939 (0.962–0.916)
PSA+25-Gene 94.8% (98.0–91.7%) 91.4% (95.1–87.8%) 90.6% (94.6–86.6%) 95.3% (98.2–92.5%) 195.5 (431.4–88.6) 0.961 (0.980–0.942)
PSA-4+25-Gene 88.6% (93.1–84.1%) 93.2% (96.6–90.0%) 91.9% (95.9–88.0%) 90.4% (94.2–86.6%) 107.3 (213.2–54.0) 0.942 (0.965–0.919)
PSA+Age+25-Gene 94.8% (97.9–91.7%) 91.4% (95.1–87.8%) 90.6% (94.6-86.5%) 95.3% (98.2–94.5%) 194.5 (429.1–88.1) 0.967 (0.984–0.950)
PSA-4+Age+25-Gene 88.5% (93.1–84.0%) 93.2% (96.6–89.9%) 91.9% (95.8–88.0%) 90.4% (94.2–86.6%) 106.6 (212.0–53.7) 0.927 (0.953–0.901)
  1. PPV positive predictive value, NPV negative predictive value, OR odds ratio, AUC area under the ROC curve, CI confidence interval, PSA-4 PSA at 4 ng/mL cutoff